Andelyn Biosciences Opens New CGT Manufacturing Headquarters
The new headquarters located in Columbus, Ohio, more than triples Andelyn Biosciences’ footprint to meet growing demand for CGT services.
On June 22, 2023, Andelyn Biosciences, a cell and gene therapy (CGT) contract development and manufacturing organization, announced the opening of its newly constructed manufacturing headquarters in Columbus, Ohio. According to a company press release, the 180,000-ft2 facility is intended to complement Andelyn’s two existing facilities in Columbus.
The new facility houses laboratory and manufacturing space, is regulatory-compliant, and more than triples Andelyn’s footprint to meet the growing demand for CGT services.
“The new facility includes 16 [C]GMP [current good manufacturing practice] modular manufacturing suites with upstream, downstream, solution prep, and filling capabilities, along with quality control labs and warehouse and corporate headquarters space,” said Wade Macedone, CEO, Andelyn Biosciences, in a company press release. “We are proud of our record of success in this demanding field, with over 2000 viral vector production runs and more than 450 [C]GMP batches delivered in support of more than 75 global gene therapy clinical trials.”
Source: Andelyn Biosciences
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
